New liquid embolic agent could shrink dangerous brain malformations
NCT ID NCT07314047
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new liquid embolic agent to treat brain arteriovenous malformations (AVMs), which are tangles of abnormal blood vessels that can cause bleeding or stroke. About 116 adults aged 18 to 80 with certain types of AVMs will receive the treatment and be followed for one year. The goal is to see if the liquid can shrink the malformation by at least 50% and improve patient outcomes compared to an existing device.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS FISTULA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Changhai Hospital
RECRUITINGShanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple breathing pattern take the sting out of dialysis?
- Ice pack on hand may ease dialysis needle pain without drugs
- Dialysis access anesthesia study pulled before starting
- New implant aims to simplify dialysis fistula monitoring
- Squeeze your way to better dialysis: handgrip training boosts fistula success
- Could a simple pill save dialysis lifelines? new trial investigates